Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Shim, M.K. | - |
dc.contributor.author | Yang, S. | - |
dc.contributor.author | Moon, Y. | - |
dc.contributor.author | Song, S. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Kim, K. | - |
dc.date.accessioned | 2021-12-03T21:42:29Z | - |
dc.date.available | 2021-12-03T21:42:29Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2021-02-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129218 | - |
dc.description.abstract | Multiple combination therapies with chemotherapeutic drugs and inhibitors of drug resistance have been effective in the clinical cases, but concerns have been raised about the severe toxicity of these chemotherapeutic drugs. Herein, we report a potent and safe combination strategy of cancer-specific doxorubicin (DOX) prodrug nanoparticles (PNPs) and B-cell lymphoma-2 (Bcl-2) anti-apoptotic inhibitor, Navitoclax, to overcome acquired drug resistance during chemotherapy. The cancer-specific PNPs were constructed by conjugating cathepsin B-specific cleavable peptide (Phe-Arg-Arg-Gly; FRRG) to DOX, resulting in FRRG-DOX that self-assembled into nanoparticles and the FRRG-DOX nanoparticles were further stabilized with the FDA-approved pharmaceutical excipient, Pluronic F68. The resulting PNPs are specifically cleaved and metabolized to free DOX in cathepsin B-overexpressing cancer cells, but they exhibited minimal cytotoxicity in cathepsin B-deficient normal cells. As expected, free DOX and PNPs induced overexpression of Bcl-2 in MDA-MB-231 cells, due to acquired drug resistance in a cell culture system. However, combination therapy with PNPs and Navitoclax showed the outstanding synergetic cytotoxicity by decreasing the expression level of Bcl-2. In MDA-MB231 breast tumor-bearing mice, intravenously injected PNPs efficiently accumulated in targeted tumor tissues via enhanced permeability and retention (EPR) effect. When combined with orally administered Navitoclax, PNPs exhibited more potent therapeutic efficacy in aquired drug resistant models than free DOX plus Navitoclax, whereas PNPs greatly reduced systemic toxic side effects in normal organs. Our cancer-specific PNP-based combination therapy with Bcl-2 inhibitor may provide a promising approach for the potent and safe treatment of acquired drug-resistant cancers. © 2020 Elsevier B.V. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.subject | Cell culture | - |
dc.subject | Cells | - |
dc.subject | Chemotherapy | - |
dc.subject | Diseases | - |
dc.subject | Drug interactions | - |
dc.subject | Mammals | - |
dc.subject | Nanoparticles | - |
dc.subject | Tumors | - |
dc.subject | Chemotherapeutic drugs | - |
dc.subject | Combination strategies | - |
dc.subject | Combination therapy | - |
dc.subject | Enhanced permeability and retention effects | - |
dc.subject | Expression levels | - |
dc.subject | Pharmaceutical excipient | - |
dc.subject | Therapeutic efficacy | - |
dc.subject | Toxic side effects | - |
dc.subject | Drug delivery | - |
dc.title | Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, K. | - |
dc.identifier.doi | 10.1016/j.jconrel.2020.10.065 | - |
dc.identifier.scopusid | 2-s2.0-85096406104 | - |
dc.identifier.wosid | 000626459100067 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.330, pp.920 - 932 | - |
dc.relation.isPartOf | Journal of Controlled Release | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 330 | - |
dc.citation.startPage | 920 | - |
dc.citation.endPage | 932 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | Cell culture | - |
dc.subject.keywordPlus | Cells | - |
dc.subject.keywordPlus | Chemotherapy | - |
dc.subject.keywordPlus | Diseases | - |
dc.subject.keywordPlus | Drug interactions | - |
dc.subject.keywordPlus | Mammals | - |
dc.subject.keywordPlus | Nanoparticles | - |
dc.subject.keywordPlus | Tumors | - |
dc.subject.keywordPlus | Chemotherapeutic drugs | - |
dc.subject.keywordPlus | Combination strategies | - |
dc.subject.keywordPlus | Combination therapy | - |
dc.subject.keywordPlus | Enhanced permeability and retention effects | - |
dc.subject.keywordPlus | Expression levels | - |
dc.subject.keywordPlus | Pharmaceutical excipient | - |
dc.subject.keywordPlus | Therapeutic efficacy | - |
dc.subject.keywordPlus | Toxic side effects | - |
dc.subject.keywordPlus | Drug delivery | - |
dc.subject.keywordAuthor | Bcl-2 inhibitor | - |
dc.subject.keywordAuthor | Cancer-specific prodrug nanoparticles | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | Inhibitor of drug resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.